Inovio Pharmaceuticals

Inovio Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer and infectious disease. Its platform pairs SynCon-designed plasmid DNA with the CELLECTRA delivery device, which uses electroporation to drive uptake of the DNA construct. The lead programme is INO-3107, now approved by the U.S. Food and Drug Administration as VOCERYQ in October 2026 to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, an HPV-driven orphan disease and the first plasmid DNA-based immunotherapy cleared in the United States; the pipeline also includes VGX-3100 for HPV-related cervical high-grade squamous intraepithelial lesions, INO-3112 in oropharyngeal cancer, INO-5401 in glioblastoma, INO-4201 for Ebola virus disease and INO-6160 for HIV. In October 2026 the company secured an $80.4 million judgment against VGXI and GeneOne Life Science over a breached 2020 supply and technology-transfer agreement, while cautioning that the defendants' financial condition may impair collection. Inovio was founded in 1979, incorporated in 1983, listed on Nasdaq in 1998, and is headquartered in Plymouth Meeting, Pennsylvania.